Safety Summary

2

• Tegaserod 4 and 12 mg/d

  • Well tolerated
  • Similar safety profile

• Diarrhea:

  • Only adverse event with higher frequency than placebo
  • Low discontinuation rate (~ 2%)

• No effects on ECG (QTc intervals or arrhythmias) or laboratory parameters

Previous slide

Next slide

Back to first slide

View graphic version